International Stem Cell (OTCMKTS:ISCO) Upgraded to Buy at ValuEngine

ValuEngine upgraded shares of International Stem Cell (OTCMKTS:ISCO) from a hold rating to a buy rating in a research note released on Tuesday, ValuEngine reports.

Shares of OTCMKTS:ISCO opened at $1.00 on Tuesday. International Stem Cell has a one year low of $0.35 and a one year high of $1.56. The company has a 50 day moving average of $0.76 and a 200-day moving average of $0.63. The stock has a market cap of $7.01 million, a price-to-earnings ratio of -4.35 and a beta of 0.77.

International Stem Cell Company Profile

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes.

Featured Article: Dividend

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.